Anti-EBNA-1 (EBV) Purified

Anti-EBNA-1 (EBV) Purified
Regulatory status
RUO
Antigen
EBNA-1 (EBV)
Clone
E1-2.5
Format
Purified
Reactivity
Epstein-Barr Virus
Variant
0.1 mg
11-303-C100
In stock
121.00 USD

0.025 mg
11-303-C025
Delivery 1 week
60.50 USD
Variant
0.1 mg
11-303-C100
In stock
121.00 USD

0.025 mg
11-303-C025
Delivery 1 week
60.50 USD
Product details
Description
References
SDS download
Isotype
Mouse IgG2b
Specificity
The mouse monoclonal antibody E1-2.5 recognizes repetitive Gly-Ala region of the Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA-1). EBNA-1 is the only viral protein consistently expressed in all malignancies associated with EBV.
Reactivity
Epstein-Barr Virus
Concentration
1 mg/ml
Preparation
Purified by protein-A affinity chromatography.
Formulation
Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
Storage and handling
Store at 2-8°C. Do not freeze.
Exbio licence note
The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.
Entrez Gene ID 3783709
UniProt ID P03211

Product specific references:

Cardinaud S, Starck SR, Chandra P, Shastri N: The synthesis of truncated polypeptides for immune surveillance and viral evasion. PLoS One. 2010 Jan 21;5(1):e8692.
PubMed
Fawzy S, Sallam M, Awad NM: Detection of Epstein-Barr virus in breast carcinoma in Egyptian women. Clin Biochem. 2008, 41(7-8):486-492.
PubMed
Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P, Burns D, McAulay K, Turner M, Bellamy C, Amlot PL, Kelly D, MacGilchrist A, Gandhi MK, Swerdlow AJ, Crawford DH: Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: Results of a phase 2 multicenter clinical trial. Blood 2007, 110(4):1123-31.
PubMed
Variant
0.1 mg
11-303-C100
In stock
121.00 USD

0.025 mg
11-303-C025
Delivery 1 week
60.50 USD
Variant
0.1 mg
11-303-C100
In stock
121.00 USD

0.025 mg
11-303-C025
Delivery 1 week
60.50 USD